3rd Annual National Opioid Crisis Management Congress
March 28-29, 2019 * Omni Resort at Champions Gate * Orlando, FL

3rd Annual National Opioid Crisis Management Congress

Day(s)

:

Hour(s)

:

Minute(s)

:

Second(s)

About the Conference

Who Should Attend?

From Hospitals/Health Systems/Health Plans/Gov’t Agencies/Law Enforcement

  • CEO
  • CFO
  • VP
  • Medical Directors
  • Behavioral Health Directors
  • Pharmacy Directors
  • Clinical Pharmacists
  • Social Workers
  • Outreach Coordinators
  • PDMP Directors
  • Pain Management Directors
  • Psychiatrists
  • Psychologists
  • Telehealth Directors
  • State Health Directors
  • Nursing Director
  • Emergency Room Directors
  • Substance Abuse & Prevention Directors
  • Pediatricians
  • Law Enforcement
  • Narcotic Enforcement
  • Physicians
  • Quality Improvement Director
  • Family Services Director
  • Clinical Directors
  • Investigators
  • Compliance Director
  • Correctional Coordinators

This Event Will Also be if Interest to:

Pharmaceutical Companies * Law Firms * Consultants * Drug Development Companies

Conference Agenda

Day One – Thursday, March 28, 2019

7:15am – 8:00am
Conference Registration & Networking Breakfast

8:00am – 8:15am
Chairperson’s Opening Remarks

8:15am – 8:55am
Keynote
Jim will discuss the current opioid epidemic, how we got here, and what is being done about it.
James “Jim” Arnold
Chief, Liaison Section Diversion Control Division
Drug Enforcement Administration, U.S. Department of Justice

8:55am – 9:35am
Medication Assisted Treatment and Supporting Communities through Collective Impact

From 2010-2013 Maricopa County (Arizona) Drug Court attempted a detox to residential program that yielded 12% outcomes in "compliance" for individuals with opioid use disorder. Since implementing medication assisted treatment (MAT) in 2015 our average of "compliance" is around 75%. Community Medical Services is fortunate enough to have great system partners and behavioral health agencies that work with the agency to provide or patients a continuum of care and additional supports for better outcomes. Maricopa County has established itself as a national leader when it comes to integrating MAT into criminal justice programs. Community Medical Services supports three different state department of corrections, six county jails and four Diversion Courts. With close communication between the courts, jails and system partners, offenders have been provided a better set of options and opportunities on the road to recovery. Maricopa County also developed and implemented the first 24-7 Opioid Treatment on Demand (OTOD) clinic, a Center of Excellence supported through AHCCCS and the State Targeted Response Grant. Utilizing Collective Impact Model for opioid use disorder was successfully implemented in Arizona and has been replicated in North Dakota, Montana and Alaska. Often these programs start with supporting high risk populations like hospital discharges after an opioid encounter or individuals that are involved with the criminal justice system. The key is supporting the incarceration facility as to maintain individuals in their recovery using MAT and then focusing on their reentry with a needs-based assessment. Audience members will leave the presentation with a working knowledge of how to develop and implement initiatives, utilizing Collective Impact, implementing and sustaining peer support, outcomes for criminal justice programs, along with an analysis of the country’s first 24-hour opioid treatment clinic and how it continues to change the ability to respond to community partners.

Michael C. White, MCJ
Director of Justice System Programs
Community Medical Services

9:35am – 10:05am
Networking & Refreshments Break

10:05am – 10:45am
Addiction Medicine: Where We Have Been and Where are Going

Physicians are relatively new to the addiction treatment landscape. The talk will cover the history of physicians’ role in treating addiction as a medical disease from the origins of organized addiction medicine through the present day. Important milestones will be described and future directions will be elucidated.

Timothy K. Brennan, MD
Director, Addiction Institute
Mount Sinai

10:45am – 11:25am
Mary “Molly” Evans, MD, MPH,
Medical Officer, Division of Unintentional Injury Prevention
Centers for Disease Control and Prevention

11:25am – 12:05pm
Barbara Bazron, PhD
Deputy Secretary, Behavioral Health Administration
Maryland Department of Health

12:05pm – 1:05pm
Lunch

1:05pm – 1:45pm
First Do No Harm: Risks of Opioid Stewardship and Strategies to Minimize Unintentional Consequences

Notwithstanding a need to improve opioid prescribing practices, these changes can also pose a risk to certain patients and communities. Dr. Coffin will describe the populations that may be at-risk for worse health outcomes, the latest data addressing potential harms of opioid stewardship, and strategies toward minimizing risk.

Phillip O. Coffin, MD, MIA, FACP, FIDSA
Director of Substance Use Research
San Francisco Department of Public Health
Division of HIV, Infectious Disease and Global Medicine
University of California San Francisco

1:45pm – 2:45pm
Panel: Prescription Drug Monitoring Program Perspective

Prescription drug monitoring programs (PDMPs) continue to be among the most promising state-level interventions to improve opioid prescribing, inform clinical practice and protect patients at risk. Although findings are mixed, evaluations of PDMPs have illustrated changes in prescribing behaviors, use of multiple providers by patients, and decreased substance abuse treatment admissions. States have implemented a range of ways to make PDMPs easier to use and access, and these changes have significant potential for ensuring that the utility and promise of PDMPs are realized. Topics to be discussed will include:
-Supporting access to legitimate medical use of controlled substances
-How to identify and deter or prevent drug abuse and diversion
-Facilitating and encouraging the identification, intervention with and treatment of persons addicted to prescription drugs
-Informing public health initiatives through outlining of use and abuse trends
-Educating individuals about PDMPs and the use, abuse and diversion of and addiction to prescription drugs

    Panelists

Johanna Buzzell
Information Systems Manager – Data and Research Coordinator
Maine Office of Substance Abuse and Mental Health Services

Rebecca R. Poston, BPharm, MHL, FCCM
Program Director
E-FORCSE Florida’s Prescription Drug Monitoring Program

Michelle R. Ricco Jonas
Program Manager
New Hampshire Prescription Drug Monitoring Program

2:45pm – 3:15pm
Networking & Refreshments Break

3:15pm – 3:55pm
Harm Reduction and the Opioid Epidemic

How do harm reduction strategies work when working with people who suffer from opioid use disorder? This presentation will highlight the benefits on the community of starting syringe exchange programs (SEP). Due to the increase in heroin overdoses in the United States, syringe exchange programs are becoming more prevalent and more states are loosening their laws in regard to SEP. Using peer reviewed articles and interviews with members of the harm reduction community, this presentation will clarify the necessity of instituting these exchanges nationwide, including the advances in the state of North Carolina, which has four cities listed in the top 25 cities with opioid abuse in 2015. The areas to be reviewed will focus on the health benefits of such programs on preventing the spread of HIV and Hepatitis C, education on basic wound and abscess care, counseling services, and ways to link people who inject drugs with proper treatment referral, along with the increased use of naloxone into these programs. This presentation will also define harm reduction and explain the principles of a harm reduction philosophy.

MStephanie Dixon
Certified Substance Abuse Counselor
Carolina Treatment Center of Fayetteville
Acadia Healthcare

3:55pm – 4:35pm
Integrating Medication Assisted Treatment with an Abstinence-Based Model of Care

This session will seek to identify challenges professionals and organizations face in integrating medication-assisted treatment and abstinence-based model of care. Common barriers and therapeutic benefits will be explored. Finally, recommendations will be offered.

Darah Meyer, MSW, LCSW
Outpatient Manager, Center for Dependency, Addiction and Rehabilitation
UCHealth

Amanada Wheeler, MSN, FNP-BC
Addiction Medicine Provider, Center for Dependency, Addiction and Rehabilitation
UCHealth

4:35pm – 5:15pm
Louisiana’s Fusion of Behavioral Health, Legislation and Primary Care to Address the Opioid Epidemic

In recent years, Louisiana’s budget shortfalls have caused an inability to fund access to all FDA approved modalities. In this session, attendees will review the follow topics to guide participants through the state’s efforts in addressing the opioid epidemic, including:
-Increased access to services as a result of grant funding
-Amended legislation and outcomes
-Prescription monitoring program to determine “hot spot” locations of specific drugs used to guide service location
-Legislation to assist provider access to prescription drug monitoring program
-Disaster planning and mandatory usage of the Methadone Central Registry
-Increased access to medicated assisting treatment through grant funding
-Implementation of the CMS guidelines

Traci M. Perry, MSN, RN
MAT-PDOA Grant Director
Louisiana State Opioid Treatment Authority

Day Two – Friday, March 29, 2019

7:15am – 8:00am
Networking Breakfast

8:00am – 8:15am
Chairperson’s Remarks

8:15am – 8:55am
Telemedicine: Another Potential Innovation to Expand Access to Treatment innovation

This session will explore the opportunities and the impediments to the use of telemedicine and telehealth in medical care, behavioral health, and services for the treatment of opiate use disorders. This session will include the regulatory and financial barriers, along with workforce matters. Finally, this session will conclude with recommendations.

Lawrence S. Brown, Jr., MD, MPH, DFASAM
Chief Executive Officer
START Treatment and Recovery Centers

8:55am – 9:35am
Promoting a Public Health Approach to the Opioid Epidemic: Legal and Policy Levers to Enhance our Nation's Response

This session will explore various federal and state laws, policies and practices helping to curb the opioid epidemic and enhance our nation's response to substance use disorders. Policies that will be highlighted include efforts to enhance evidence based treatment in the criminal justice system, improving access to services in rural areas hard hit by the opioid epidemic, and other innovative approaches being implemented across the country. The session will also identify the legal or policy barriers that may limit a community's ability to pursue such efforts.

Regina LaBelle
Principal
LaBelle Strategies LLC
Former Chief of Staff, Executive Office of the President, Office of National Drug Control Policy (2012-2017)

9:35am – 10:15am
Opioid Use Disorder: The New Patient

Opioid use disorder (OUD) continues to be one of the biggest public health challenges of recent history. The early years of what is now called the “Opioid Epidemic” saw primarily prescription painkiller misuse and abuse. Now, however, as the statistics relate, many OUD patients have moved to heroin. With this move, there have been significant other changes in the presentation of this populations. This presentation with discuss the related changes in OUD patients and the treatment challenges these changes present. Data collected from a nationwide network of treatment centers will be presented and treatment implications for this changing population will be reviewed.
Learning Objectives:
-Review the history and progress of the Opioid Epidemic in America.
-Identify the myths, realities and changes in the opioid use disorder patient.
-Discuss recent changes in the opioid use population and their implications for identification and treatment.

Siobhan A. Morse, MHSA, CRC, CAI, MAC
Division Director of Clinical Services
Addiction Services Division/Universal Health Services
Foundations Recovery Network

10:15am – 10:45am
Networking & Refreshments Break

10:45am – 11:25am
Convening Strategies to Address the Opioid Epidemic

Recent data from the Massachusetts Department of Public Health suggests a 5% decrease in opioid-related overdose deaths in the state from 2016 to 2017. Specific communities within the state also experienced similar improvements. In Worcester, MA, the number of opioid-related emergency medical services incidents decreased by 6.7% from 2016 to 2017, although overdose deaths have remained constant. Since the emergence of the opioid epidemic, the city of Worcester has launched a community-wide response to address this public health issue. This effort addresses the wide spectrum of social determinants of health, from childhood trauma in the public schools to incarceration. In order to fight this epidemic, it is important to bring all stakeholders to the table and decide what and how each one contributes. The Worcester Department of Health and Human Services focuses on simultaneously engaging institutions addressing the upstream determinants and downstream impacts of addiction, including grassroots and policy organizations. Doing so creates a strong and united community response necessary to combat the opioid epidemic.

Matilde Castiel
Commissioner of Health and Human Services
The City of Worcester

11:25am – 12:10pm
Prescription Opioid Abuse: Challenges and Opportunities for Insurers

Insurance companies are taking measures to combat the staggering opioid addiction numbers and deaths. Prescription opioid abuse and addiction are serious problems with growing societal and medical costs, resulting in billions of dollars of excess costs to health insurers annually. The cost to public and private insurance companies of prescription painkiller abuse, treatment and diversion is an estimated $72.5 billion a year. This session will address payer strategies to control these costs, mitigate financial risks and improve Quality (measurable outcomes) while supporting safe use of prescription opioid medications for patients with chronic pain.

Sander Koyfman, MD
Behavioral Health Medical Director
WellCare Health Plans, WellCare of NY

12:10pm – 12:50pm
Integrated and Coordinated Opioid Treatment Care and Improving Access to Addiction Care

Research has proven that effective care coordination increases efficiency and improves clinical outcomes and patient satisfaction. And while connecting people to treatment and recovery support has been shown to be effective and can save lives, the addiction care system continues to face tremendous change and upheaval. This session will assist you in the development of strategies to improve the collaboration between opioid treatment providers and the systems needed to coordinate care. You will also learn recent developments aimed at improving access to addiction care, including medication-assisted treatment. Topics will include:
-Potential future developments related to substance use disorder treatment
-The future of medication assisted treatment, delivery system reforms, and opportunities available for improving policy moving forward
-Strategies for getting ahead of the problem, and how upstream prevention action can restore hope and lead to a brighter and healthier future for generations to come

Stephen M. Taylor, MD, MPH, FASAM
General, Child/Adolescent and Addiction Psychiatrist
Medical Director, NBA/NBPA Player Assistance/Anti-Drug Program
Chief Medical Officer, Behavioral Health Division
Pathway Healthcare, LLC

12:50pm
Conference Concludes

Workshop – Thursday, March 28, 2019

5:30pm – 7:30pm
How Medication-Assisted Treatment Can Improves Outcomes for Patients With Opioid Use Disorder
Medication-assisted treatment (MAT) is an effective response to opioid use disorder and can be a life-saving and cost-saving intervention. It is the use of medications, in combination with behavioral therapies, to provide a whole-patient approach to the treatment of substance use disorders. Individuals receiving MAT often demonstrate dramatic improvement in addiction-related behaviors and psychosocial functioning. MAT is proven to significantly reduce illicit opioid use compared with nondrug approaches, and increased access to these therapies can reduce overdose fatalities. However, MAT is often unavailable to those in need of it because of inadequate funding for treatment programs and a lack of qualified providers who can deliver these therapies. This workshop will address various types of approved medications, screening and assessment tools, and best practices for patient care.

Jake Nichols, PharmD, MBA
Chief Executive Officer

Strategic Recovery Resources, LLC
Jake Nichols is a pharmacist in long‐term recovery with extensive experience in community
pharmacy, academia, primary care, managed care, and pharmaceutical industry. He specializes
in the treatment of substances use disorders, with a focus on medication assisted treatment.
Through his fifteen‐year struggle with substance abuse, he found his calling in the field and has
dedicated his career to helping patients and their families suffering from this debilitating
chronic disease. By providing clinical support for clinicians treating patients with substance use
disorder and serving as a vocal advocate for treatment, Jake has established himself as a key
resource within the field. He has spoken at well over 100 pharmacy, nursing, and
medical schools across the country in the past 5 years, sharing his story with students and
faculty, and he regularly facilitates patient and parent support groups. Jake has recently
established his own education and clinical consulting group called Strategic Recovery Resources of which he is owner and CEO. He is also currently employed by Pear Therapeutics as a
medical science liaison. Jake received his Doctor of Pharmacy Degree from the Massachusetts
College of Pharmacy in 2000 and his Master’s Degree in Business Administration from UMass
Boston in 2007.

Featured Speakers

James “Jim” Arnold

James “Jim” Arnold

Chief, Liaison Section Diversion Control Division

Drug Enforcement Administration, U.S. Department of Justice

Michael C. White, MCJ

Michael C. White, MCJ

Director of Justice System Programs

Community Medical Services

Timothy K. Brennan, MD

Timothy K. Brennan, MD

Director, Addiction Institute

Mount Sinai

Barbara Bazron, PhD

Barbara Bazron, PhD

Deputy Secretary, Behavioral Health Administration

Maryland Department of Health

Phillip O. Coffin, MD, MIA, FACP, FIDSA

Phillip O. Coffin, MD, MIA, FACP, FIDSA

Director of Substance Use Research

San Francisco Department of Public Health
Division of HIV, Infectious Disease and Global Medicine
University of California San Francisco

Rebecca R. Poston, BPharm, MHL, FCCM

Rebecca R. Poston, BPharm, MHL, FCCM

Program Manager

E-FORCSE Florida’s Prescription Drug Monitoring Program

Michelle R. Ricco Jonas

Michelle R. Ricco Jonas

Program Manager

New Hampshire Prescription Drug Monitoring Program

Stephanie Dixon

Stephanie Dixon

Certified Substance Abuse Counselor

Carolina Treatment Center of Fayetteville
Acadia Healthcare

Darah Meyer, MSW, LCSW

Darah Meyer, MSW, LCSW

Manager Clinic Operations ,Center for Dependency, Addiction and Rehabilitation

UCHealth

Traci M. Perry, MSN, RN

Traci M. Perry, MSN, RN

MAT-PDOA Grant Director

Louisiana State Opioid Treatment Authority

Jake Nichols, PharmD, MBA

Jake Nichols, PharmD, MBA

Chief Executive Officer

Strategic Recovery Resources, LLC

Lawrence S. Brown, Jr., MD, MPH, DFASAM

Lawrence S. Brown, Jr., MD, MPH, DFASAM

Chief Executive Officer

START Treatment and Recovery Centers

Regina LaBelle

Regina LaBelle

Principal

LaBelle Strategies LLC
Former Chief of Staff, Executive Office of the President
Office of National Drug Control Policy (2012-2017)

Siobhan A. Morse, MHSA, CRC, CAI, MAC

Siobhan A. Morse, MHSA, CRC, CAI, MAC

Division Director of Clinical Services , Addiction Services Division/Universal Health Services

Foundations Recovery Network

Matilde Castiel

Matilde Castiel

Commissioner of Health and Human Services

The City of Worcester

Stephen M. Taylor, MD, MPH, FASAM

Stephen M. Taylor, MD, MPH, FASAM

General, Child/Adolescent and Addiction Psychiatrist,General, Child/Adolescent and Addiction Psychiatrist,Chief Medical Officer, Behavioral Health Division

Pathway Healthcare, LLC

Venue

Omni Orlando Resort at ChampionsGate

Omni Orlando Resort at ChampionsGate
1500 Masters Boulevard
Champions Gate, FL 33896
800-843-6664

“Mention BRI Network for the Discounted Rate of $189/night”

Sponsors and Exhibitors

TBA

FAQ

Are there group discounts available?

  • Yes – Register a group of 3 or more at the same time and receive an additional 10% off the registration fee

Are there discounts for Non-Profit/Government Organizations?

  • Yes – please call us at 800-743-8490 for special pricing

What is the cancellation policy?

  • Cancellations received 4 weeks prior to the event will receive a refund minus the administration fee of $225. Cancellation received less than 4 weeks prior to the event will receive a credit to a future event valid for one year.

Can the registration be transferred to a colleague?

  • Yes – please email us in writing at info@brinetwork.com with the colleague’s name and title

Where can I find information on the venue/accommodations?

  • Along with your registration receipt you will receive information on how to make your hotel reservations. You can also visit individual event page for specific hotel information. The conference fee does not include the cost of accommodations.

What is the suggested dress code?

  • Business casual. Meeting rooms can sometimes be cold so we recommend a sweater or light jacket
Request Brochure

Register Your Team Today!

Register Now
Ask A Question

Be A Thought Leader And Share!

Pin It on Pinterest